Clinical trials: Percutaneous Coronary Intervention Patients
Anterior Wall Acute Myocardial Infarction
Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
The primary objective of the study is to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in treatment of anterior acute myocardial infarction (AMI) patients who have undergone successful…
- Trial name
- IC-HOT (NCT02603835)
- Testing
- SSO2 Therapy
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- TherOx
Coronary Artery Disease, Percutaneous Coronary Intervention
Patient Centered Machine Learning Model for Bleeding and Ischemic Risk
Dual antiplatelet therapy (DAPT) is indicated in all patients undergoing coronary stent implantation to prevent ischemic recurrencies despite an increased risk of bleeding.
- Trial name
- xDAPT (NCT06089304)
- Testing
- Percutaneous coronary intervention
- Where
- United States
- Volunteers
- 19,000 people
- Sponsor
- Abbott Medical Devices
ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI)
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
The goal of this clinical trial is to learn if giving the drug empagliflozin before versus after a heart procedure called primary PCI (percutaneous coronary intervention) affects how much heart muscle is damaged during a heart…
- Conditions
- ST-elevation Myocardial Infarction (STEMI), Acute Myocardial Infarction (AMI), Coronary Artery Disease
- Trial name
- TEMPO-STEMI (NCT07749014)
- Testing
- empagliflozin
- Where
- Pakistan
- Volunteers
- 480 people
- Sponsor
- Rehman Medical Institute - RMI
Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction
Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
The administration of these drugs is realized according to the European Society of Cardiology guidelines. All patients will be pretreated with aspirin 300 mg orally, heparin iv to maintain an activated clotting time of >250 sec…
- Conditions
- Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, Unstable Angina
- Trial name
- NCT02032290
- Testing
- Assessment of Coronary Flow Reserve, Percutaneous coronary intervention, ticagrelor loading
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Azienda Policlinico Umberto I
Coronary Artery Disease, Diffuse Coronary Artery Disease
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
The primary objective of the study is to assess the safety and the efficacy of a hybrid percutaneous coronary intervention (PCI) strategy combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik…
- Conditions
- Coronary Artery Disease, Diffuse Coronary Artery Disease, Percutaneous Coronary Intervention (PCI)
- Trial name
- BIOHYBRID (NCT06710210)
- Testing
- PCI with a bioresorbable scaffold and drug-coated balloon(s), PCI with drug-eluting stent(s)
- Where
- 4 sites in Switzerland
- Volunteers
- 150 people
- Sponsor
- University Hospital, Geneva
Chronic Coronary Syndrome, Acute Coronary Syndromes
Optimal LDL-C Target in High-risk Patients After PCI
Extensive evidence from epidemiological, genetic, and randomized controlled trials (RCTs) of lipid-lowering therapies has firmly established a causal relationship between low-density lipoprotein cholesterol (LDL-C) and…
- Conditions
- Chronic Coronary Syndrome, Acute Coronary Syndromes, Percutaneous Coronary Intervention, High Risk Patient
- Trial name
- REC-SAFETARGET (NCT06821711)
- Testing
- Intensive LDL-C control, Conventional LDL-C control
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Xijing Hospital
Acute Coronary Syndromes
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors With Statin for ACS Patients
Cardiovascular diseases (CVDs) remain the leading cause of death globally, with a dominant contribution from atherosclerotic CVD (ASCVD).
- Trial name
- NCT07736313
- Testing
- PCSK9 inhibitor plus rosuvastatin 20 mg tab, Rosuvastatin 20 Mg Oral Tablet
- Volunteers
- 120 people
- Sponsor
- Assiut University
ST Elevation Myocardial Infarction, Arrhythmia Ventricular
Different Reperfusion Timing and Ventricular Arrhythmias in STEMI Patients
The aim of this study was to investigate the association between different reperfusion timing and ventricular arrhythmias (VAs) to provide evidence for clinical decision-making for patients with ST-segment elevation myocardial…
- Trial name
- NCT04660474
- Where
- China
- Volunteers
- 517 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Dual Anti-platelet Therapy
Aspirin-Free Strategy After 3-6 Month Dual Antiplatelet Therapy in Acute Coronary Syndrome
This randomized controlled trial aims to evaluate the safety and efficacy of an aspirin-free strategy after 3-6 months of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) who have undergone complete…
- Trial name
- NCT07736196
- Testing
- Aspirin-Free Strategy, Dual Antiplatelet Therapy
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN)
Beyond the Mehran Risk Score: Predictive Value of Total Ischemic Time for Contrast-Induced Nephropathy in ST Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
Contrast-Induced Nephropathy (CIN) is a serious complication following primary percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI).
- Conditions
- ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN), Acute Kidney Injury
- Trial name
- NCT07826572
- Testing
- Total Ischemic Time Evaluation
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assiut University
Ischem Heart Disease, Primary Coronay Intervention
CHAOS Registry Study
INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart valves, or venous thromboembolism.
- Conditions
- Ischem Heart Disease, Primary Coronay Intervention, Oral Anticoagulants, Atrial Fibrillation
- Trial name
- CHAOS (NCT03558295)
- Testing
- Oral Anticoagulant
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
ST Elevation Myocardial Infarction
The Relationship Between Myonectin Concentration and the Course of ST-segment Elevation Myocardial Infarction
The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI).
- Trial name
- NCT05700773
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Michał Jaśkiewicz
Coronary Artery Disease
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Numerous studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel treated patients and that individuals with reduced response have an increased risk of recurrent ischemic events.
- Trial name
- NCT02065479
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
High-risk Percutaneous Coronary Intervention
Magenta Elevate™ EFS in High-Risk PCI Patients
The Elevate™ EFS study is designed to evaluate the safety and feasibility of the Magenta Elevate™ percutaneous Left Ventricular Assist Device (pLVAD) System in patients undergoing non-emergent, high-risk percutaneous coronary…
- Trial name
- NCT05727059
- Testing
- The Elevate™ System
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Magenta Medical Ltd.
Coronary Artery Disease, Myocardial Ischemia
Genoss DES Prospective Multicenter Registry
This registry is a clinical post-market evaluation of the Genoss DES in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT03045913
- Testing
- Genoss DES
- Where
- 17 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Young Jin Youn, MD, PhD
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet…
- Trial name
- NCT05911659
- Testing
- Ticagrelor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mina Wageh Mohareb
Coronary Artery Disease, Diabetes Mellitus
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2…
- Trial name
- NCT02742987
- Testing
- Ticagrelor, Clopidogrel, Standard medical therapy
- Volunteers
- 42 people
- Sponsor
- Campus Bio-Medico University
ST-elevation Myocardial Infarction
Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction
ST-elevation myocardial infarction (STEMI) has a serious health threaten to population. PCI, which can timely restore the blood flow to the ischemic myocardium, is a well-proved measure in STEMI management.
- Trial name
- GOODI (NCT03074214)
- Testing
- percutaneous coronary intervention
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Shengjing Hospital
Percutaneous Coronary Intervention, Femoral Sheath Removal
Effect of Virtual Reality During Femoral Sheath Removal
This randomized controlled study was conducted to evaluate the effect of virtual reality glasses used during femoral sheath removal on pain, anxiety, and vital signs in patients undergoing percutaneous coronary intervention.
- Trial name
- NCT07653763
- Testing
- Virtual Reality, Routine Care
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hasan Kalyoncu University
Acute Coronary Syndromes
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
The purpose of this study is to determine if Apixaban is safer than a Vitamin K Antagonist given for 6 months in terms of bleeding in patients with an irregular heart beat (atrial fibrillation) and a recent heart attack or a…
- Trial name
- NCT02415400
- Testing
- Apixaban, vitamin K antagonist, Acetylsalicylic acid
- Where
- 626 sites in United States, Argentina and 35 more
- Volunteers
- 4,614 people
- Sponsor
- Bristol-Myers Squibb